Company ProfileCompany Profile


Aiming to be a global niche top manufacturing company
We will continue to take on the challenge.

 A quarter of a century has passed since JTEC Corporation was founded in December 1993 and the path that we have taken has not been so smooth.

 Throughout these years, we have consistently pursued results without fear of failure, taking on challenges before anyone else, under our management philosophy of "creating products with unique technologies that have never existed before and contributing broadly to society.
 We have focused our management resources on the two businesses to expand our business scale. One, we are engaged in the optical business, focusing on X-ray focusing mirrors for synchrotron radiation, which have been successfully commercialized based on the research results of Osaka University and RIKEN. The other, the life science and equipment development business, focusing on various automated cell culturing devices developed based on the unique cell culture technology cultivated since the establishment of the company.

 The large synchrotron radiation facility "SPing-8" in Hyogo Prefecture and the X-ray free-electron laser facility "SACLA" are used for basic and applied research in various fields such as medicine, life sciences, and materials science, as well as for product development in many industrial fields. Our X-ray mirrors for synchrotron radiation have been installed at such large synchrotron radiation facilities and X-ray free-electron laser facilities not only in Japan but also many facilities worldwide, and have earned a high reputation as one of the world's top high-precision mirrors and selected by the Ministry of Economy, Trade and Industry (METI) as one of the "100 Global Niche Top Companies for 2020" in the materials and chemicals sector.
 We are actively pursuing joint development with leading companies in various fields in order to expand our products to other industrial fields such as semiconductor, space, and medical fields, and will continue to boldly challenge to differentiate our products from our global competitors and pursue competitive advantage.
 In addition to the atomistic nanofabrication technologies such as EEM and RADSI/MSI, which are the original atomistic nanofabrication technologies that make this X-ray mirror possible, we are also working on new nanofabrication technologies such as CARE, which uses catalysis, PCVM, which uses high-pressure plasma, and new nanofabrication technologies such as CMM. Moreover, we are also promoting the practical development of measurement technology. In terms of equipment development, we are developing various types of nanoprocessing equipment by applying our proprietary nanoprocessing technology to high-precision mask substrates for next-generation semiconductors, for example, which require nanometer-accurate thickness distribution, and to crystal wafers for high-precision crystal oscillators, for which demand is increasing due to the commercialization of 5G services and the use of IoT.

 On the other hand, in the area of automated cell culture systems, we have successfully developed a 3D cell culture system in the field of regenerative medicine, for which demand is expected to grow in the future, based on our proprietary 3D floating culture technology, Cell Float®, for which we have conducted research and development for many years in collaboration with the National Institute of Advanced Industrial Science and Technology (AIST). We will continue our efforts to contribute to society as soon as possible by conducting clinical research in collaboration with medical schools of Osaka University and Yokohama City University and other institutions.
 In the field of drug discovery, we are focusing on the development of general-purpose products as well as the manufacture and sale of various custom-made automated cell devices, which we have been promoting since our establishment. In particular, we are promoting the development of technology and products related to iPS cells, as well as the development of products for the cultivation of organoids (also known as "mini-organs"), which are expected to be used as a discovery tool for next-generation therapeutic drugs and are useful in the treatment of new types of coronavirus infection.
 In the field of life science, for example, various culture technologies have been proposed for various types of culture equipment, and new technologies and services are being created one after another. We will continue to grow in response to these changes and aim to become the leading company in cell culture-related equipment.
 Last of all, we are pleased to announce that we have moved our stock listing from the Mothers Market to the First Section of the Tokyo Stock Exchange. We will take this opportunity to challenge new fields, improve our technical capabilities, and build a new pillar of business to further expand our operations and increase our corporate value.

President of JTEC CorporationTakashi Tsumura